Cyclin-dependent kinase 2 (CDK2)

Overview

Cyclin-dependent kinase 2 (CDK2) is a serine/threonine protein kinase that functions as a core regulator of cell-cycle progression. In normal biology, CDK2 acts in concert with cyclins to control transitions through the G1/S boundary and S phase, thereby coordinating DNA replication and cell proliferation. Because of this central role in cell-cycle control, CDK2 is widely studied in oncology and drug discovery as a target for suppressing uncontrolled tumor growth.

In recent biomedical research, CDK2 has been especially relevant in Cancers that evade Cdk4/6 inhibitor therapy or show CCNE1 amplification, both of which can indicate dependence on CDK2-driven cell-cycle signaling. It is also frequently evaluated alongside related kinases such as cyclin-dependent kinase 6 (CDK6), cyclin-dependent kinase 1, and Aurora kinase A (AURKA), as well as pathway-associated proteins including BCL2 apoptosis regulator, caspase-3, and Mki67, to understand how cell-cycle arrest, apoptosis, and proliferation are altered by candidate therapies.

Recent Publications Summary

Recent studies have continued to position Cyclin-dependent kinase 2 (CDK2) as an important therapeutic target in cancer, particularly in settings of resistance to CDK4/6 inhibition or CDK2-driven proliferation. A structure-guided medicinal chemistry campaign identified B10 and B12 as cereblon-based molecular glue degraders that selectively degrade CDK2 through a noncanonical recruitment mode centered on CDK2 Glu57, leading to reduced retinoblastoma (Rb) phosphorylation, G1/S-phase arrest, and suppression of CDK2-dependent cell proliferation; B12 also showed improved pharmacokinetics, oral bioavailability, and intratumoral CDK2 degradation in vivo 42334090Jun. In a separate optimization effort, compound 19 was developed as a potent CDK2 inhibitor with good selectivity over CDK4 and CDK1, and its pharmacokinetic profile supported evaluation in a CDK2 xenograft model, where it achieved nearly 80% tumor growth inhibition 42328801Jun.

Additional inhibitor-discovery studies reported several small-molecule series with CDK2 activity and anticancer effects. A set of 4,5,6,7-tetrahydrobenzo[b]thiophene carboxamides showed cytotoxicity against HepG-2, MCF-7, and MDA-MB-231 cells, with compound 11 displaying the strongest CDK2 inhibition, nearly threefold greater than roscovitine, and inducing G0/G1 arrest in MDA-MB-231 cells 42210722May. Likewise, 1,2,4-triazolo[1,5-a]pyrimidine derivatives were designed as dual EGFR/CDK2 inhibitors for colorectal carcinoma; lead 22 produced a CDK2 IC50 of 0.03 μM, and the active compounds induced G2/M arrest and apoptosis in HCT-116 cells with accompanying changes in Bax, cytochrome c, caspase-3, VEGF, AKT-1, and Bcl-2 42200498May. In breast-cancer-oriented in silico screening, Z-ajoene from garlic was predicted to bind strongly to CDK2 among other biomarkers, supporting its potential as a multi-target agent 42090396May.

CDK2 was also implicated in studies of natural products and mechanistic cancer biology. Aucan, a dibenzofuran analog from Usnea, was identified as a key-targeting compound in glioblastoma models; functional studies using CDK2 knockdown and overexpression supported CDK2 as a mediator of Aucan’s effects, with the compound downregulating CDK2, suppressing PI3K/AKT signaling, reducing proliferation, and increasing apoptosis in vitro and in vivo 41846012Mar. In lung adenocarcinoma, the circRNA-encoded protein RIPK1-98 was reported to modulate CDK2-dependent cell-cycle regulation and thereby promote tumor proliferation in cellular and animal models 41825439Mar. In parallel, computational work on Pinellia ternata phytochemicals prioritized CDK2 among core lung-cancer targets, and molecular docking/simulation analyses were used to explore target engagement 42149884May.

What Changes, What Holds

1. CDK2 can now be degraded selectively to suppress its signaling in tumors
REINFORCES The new degrader work strengthens the therapeutic case for CDK2 in cancer rather than changing its basic biology: it supports the established view that CDK2-driven proliferation can be blocked to reduce Rb phosphorylation and arrest cells in G1/S. The added value is translational, showing that selective degradation, not just inhibition, can be made pharmacologically useful and may improve in vivo exposure and tumor delivery 42334090Jun42328801Jun.

2. New inhibitor series broaden the CDK2 drug-discovery landscape without changing the target’s role
REINFORCES These studies extend the existing oncology-focused use of CDK2 by adding more chemical matter with antiproliferative activity, including dual-target designs and natural-product-inspired screening. They do not alter the baseline account that CDK2 is a cell-cycle regulator relevant to cancer; instead, they sharpen the practical point that CDK2 remains a tractable kinase for medicinal chemistry, with downstream effects on arrest, apoptosis, and biomarker modulation 42210722May42200498May.

3. CDK2 remains a mechanistic node in tumor biology beyond direct inhibitor development
REINFORCES The new mechanistic and computational studies reinforce CDK2’s centrality in cancer cell-cycle control and tumor proliferation, including as a mediator of natural-product effects and as a target embedded in broader pathway networks. They do not displace the established account of CDK2 as a regulator of G1/S progression; rather, they add context that CDK2 can sit downstream of diverse oncogenic inputs and may be useful as a convergence point for multi-target strategies 41846012Mar41825439Mar.

Overview update candidates: selective CDK2 degradation as a therapeutic strategy; additional inhibitor series and dual-target designs; mechanistic support for CDK2 as a convergence node in tumor proliferation.